Member Info for rhubarbmk2

Novice; KTH222 is a prospect in and of itself. It's placed in an area of poorly-met clinical lead, and I've looked at published data which suggests it may not be too shabby at all. Worth bearing in mind that 2-3 more if these "types" may be brought in this year. Keep your eyes peeled, because these will turn the backbone of the company going forward.

IAR - rather than all these accusations; what would you like to happen, apart from to know Suzy's salary? How will you act in light of that information? Will you sell your shares, or is it just an exercise in trying to smoulder resentment amongst the shareholders? Would you like to replace her? Who with? How much do you want to pay for one? 4X Suzy's salary for a silver tongue, with some very generous sweet equity should do it. I’m happy to table an extra-ordinary resolution with a super suggestion, which I suspect will not be forthcoming, and which would undoubtedly be voted down.

What would you do with 301? Would you make the Japanese "reveal" themselves (it's not too hard to work out who it likely is for an inquisitive chap like yourself, btw), potentially blowing any chance of co-dev? Would you just pull the plug? Would you fundraise to further an in-house Phase 1 with your middle finger in the air?

As I’ve said before, I have partially agreed with your will to see a slightly less conservative comms reach. The lines are incredibly open, like no other company, but the content can be (imo) a tad sub-NOMAD allowance, and the Q and A is now not exacting its intention, as it seems to have manifested into a vehicle by which folk can throw dirt at the CEO, who was actually trying to do this for the shareholders. They don’t need to do this, and I wouldn’t blame them if they pulled it. It certainly isn’t helping the SP due to the “quality” of some of the questions, and the provoked “stand-offs”. Good lord; to be an AIM CEO.

You have a grievance. I suspect you are sitting on a paper loss and just want to force something out to raise the SP, so you can get out. You won't be alone in that, and there’s nothing wrong on this forum with contributing some negative appraisal. But drop the tomatoes, and tell us - succinctly - your suggestions; what you'd like to see released, how you'd gauge a reasonable response, and where you would like to see the company in six months, in order to retain your shares. Be mindful of pharma bureaucracy and timelines, however. You’re a smart chap, so it would be good feedback to get for the BOD.

I'd take 301 over DCA any day, because it's efficacy in various disease settings is still largely questionable, not to mention that it can cause neuropathy and a couple of other nasties. Knocks out other healthy cells, too; not ideal. Besides, I think it is probably quite hard to patent now, which would obv hinder its wider scale development. Good luck, however, if it is helping some, but it wouldn't be my choice. Like VAL, I like medicines to have a tempered safety profile, especially in non life-threatening disease contexts. OB- sweet anecdote pal.

Good man. You know you can't write "Iceman" on the form, though, no? I don't think the FCA would go for that.

hehe - blinking heck Iceman - where's your TR-1 son?

A show of unity and confidence - probably commensurable with the fact that they pay themselves limited salaries; happy with that personally.

Excellent value!

I thought I'd try my luck pal. :-)

I do know that the financial steers must be able to buy and sell one trade, because I once did two TR-1s and they were both followed swiftly with a 1 trade; the Company involved hadn't even been notified at that point.

There it is; someone's having a laugh, but then a stuck clock is always right at some point.

A nice chevy in cobalt blue would do me, cobaltblue.

You're right, mind, don't tell them your name, Pike! Learn my lesson! :-)

Not me pal. Maybe someone like me at the LSX conference saw Suzy's webinar, looked at the 201 poster, saw the Market Cap on google, and ran to login to their interactive investor account.

At least we have a good old laugh about it, old son. Better than the SNG board, where they collectively get Brewer's droop whenever a new vaccine is release :-)

Tell them they're a bunch of pervs and the double entendre had never entered anyone's mind, apart from theirs.

RB - germane and thoughtful insight, as per.

I miss the dear fellow too. Maybe he'll come back one day at 7am; he'd certainly brighten it up. That being said, he could probably inflate the SP back to 40 with no news. :-)

BTW if no one wants to take 201 into 100 patients, at higher doses, to find a proper max tolerated administration, and watch the scans/PSA, then either I'm not privy to something, or I'm changing careers to fulfil my life long ambition of becoming a dancer.

As RB says, take comfort in a 15M MCap. Just one of the preclinical assets that they will bring in over the next few months could probably be sold on for more than that within a year or two.

In fact, I've recently been reading the published data/info for KTH222. It doesn't look too shabby and there's a nice paper referenced on the Val website. It's a very well conducted and thoroughly critiqued evaluation. In fact, it looks like Kalos are already running the pre-IND safety studies, so it's quite a bit further along that I thought. I don't know the ins and outs of the contract with VAL, but this alone may be potentially "worth" a chunk of the MCap for an investigational drug in ovarian cancer, if it were any other Company.

We have the opposite "problem" to many Biotechs, with MCaps of multiples of ours. We are short pre-clinically, but have clinical assets. The former is much easier to backfill than to forward fill the latter!

Waiting for an RNS :-)

Hazard a guess end of the year, but they'll need some reddies if they bring anything else in house, and they'll definitely do that. 100%.

In theory; reasonable.

The board will probably be looking for an upfront payment of some sort, because they'll be wary of previous placings. I'd imagine that, failing any upfront payments, they'll still be very keen to put a new peg down at this juncture in the new management. Ironically, with something concrete in the pipeline, e.g. a guaranteed payment at the commencement of a 201 Phase 2b/3, or 301 Phase 1, it would easier for the company to raise. I'd even be tempted to buy more myself. But I'd want to see something solid, before dipping in again, personally. In any case, they have some months before that would be agreed (unless there's a third party dilution), so there's plenty of time for something material to happen before then.

Also, I'd obviously like them to get an established partnership sooner rather than later, as we all would, but don't forget that no deal in the short-term is better than a rushed and poor deal to get the shareholders off their backs.

I'm not a patient person, but sometimes it is worth it.

Porky - please have a look at the website and read through a few pages on here since around the end of September. VAL201 is awaiting a partner to progress to a larger clinical study. The Share, by my reckoning, has about a 90% concentration to long-term holders now, with a very limited free-float. So it moves up and down on very limited transaction. Don't worry about imminent dilution - not going to happen in the short-term, and the Company has new management which is very different now.

It's not a low-risk investment, but there's a relatively small Market Cap, so any huge plummet would be buffered by this, with a potential large upscale in SP. Again, I'd suggest researching the website and this forum, and then decide if you would like to pay your money and take your chance, as we have done. Essentially, most of us are here to sink or swim together, based upon what we have divulged together from the public domain, with a little speculation thrown in :-) Good luck in your investments.

Having said that; regarding 201/301, this could be a genius way to drive any interest to fruition. If 301 really has been approved and protected for other reproductive hyperplasias, then its "value" has now materially, and likely substantially, increased. So it could be a very cunning move, or, I could, as usual, be overthinking, and the QandA will downplay it as "uneventful small cap biotech part-and-parcel, well within the remit of routine bog- standard housekeeping" ;-)